mRNA vaccines

By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology advancing but not with our wellbeing in mind as everything seems to be thriving...

Key Takeaways: News of marketing approval for China’s first mRNA vaccine falls flat with investors, who worry the drug is being rushed to market before Phase 3 trials are complete As the pandemic abates, the market for the vaccine is shrinking rapidly By Ellie Si Timing is everything, so...

Major Wall Street indices closed mixed on Tuesday, with the Dow Jones falling over 1%, pressured by Goldman Sachs Group Inc (NYSE: GS) earnings. The S&P 500 closed marginally lower at 0.2%, while the Nasdaq Composite ended the session 0.14% higher. Meanwhile, here are the five stocks that...

Global merger and acquisition activity topped $1 trillion in the second quarter of 2021, with the U.S alone topping $500 billion. This was the third quarter in a row that this happened globally and in the U.S. The second quarter started strong with four of the five largest deals announced in the...

The FDA granted Fast Track designation Moderna Inc's (NASDAQ: MRNA) mRNA-1345, its investigational single-dose mRNA vaccine against the respiratory syncytial virus (RSV) in adults older than 60 years of age. The respiratory syncytial virus is a common respiratory virus that...

A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi SA (NASDAQ: SNY) has announced a $3.2 billion buyout for Translate Bio. Sanofi will pay $38 in cash for each...

The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) Clinical Trial Application (CTA) to advance ARCT-154 COVID19 vaccine candidate targeting variants of concern. The ARCT-154 Phase 1/2/3 clinical study is a randomized, observer-blind...

Autolus Therapeutics plc (NASDAQ: AUTL) has granted Moderna Inc (NASDAQ: MRNA) an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets. Autolus would be eligible to receive an...

A well seasoned SPAC management team announced a SPAC deal Tuesday to bring a cell programming company public. The SPAC Deal: Ginkgo Bioworks is going public in a SPAC deal with Soaring Eagle Acquisition Corp (NASDAQ: SRNG) that values the company at a pre money equity value of $15 billion. Soaring...